Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nordion to sell Belgian business to Best Medical

This article was originally published in Clinica

Executive Summary

Nordion has agreed to sell its Belgian operations to Best Medical Belgium, part of the Best Medical International group. The deal does not include Nordion's microsphere-based anticancer treatment TheraSphere, which showed promising results in a trial in liver cancer last year (www.clinica.co.uk, 8 October 2010). Best Medical will acquire Nordion's Glucotrace fludeoxyglucose (FDG) imaging agent, its industrial radiography business, Agiris, and its radiochemical business, which produces generic cyclotron and reactor isotopes used in nuclear imaging. It will also gain all of Nordion's Belgian employees, except those involved in developing TheraSphere, and its Belgian facilities, based in Fleurus. Ottawa, Canada-based Nordion, previously called MDS Nordion, decided to exit or restructure its Belgian business last year after the segment made a loss. Financial details of the deal were not disclosed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT096782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel